J&J CEO Joaquin Duato on 2024 guidance, product pipeline and long-term growth outlook

The Janssen Pharmaceutical Companies of Johnson & Johnson

Drug Pipeline Is Well Positioned for 2024, Says J&J CFO

J&J Sales Analysis by Helena (2020-2024Q1)

Why The Biggest Pharma Company In The U.S. Is Breaking Up

Fang talks about working at J&J in Pharmaceuticals R&D

Leading Innovation in Neuroscience

Johnson & Johnson Pharmaceutical Growth

Big Data Hits “Primetime” at Janssen Pharmaceutical Co’s of J&J: Inside Their AI-Fueled R&D Approach

Fireside Chat with Dr. William Hait, Chief External Innovation & Medical Officer, Johnson & Johnson

Takeda says it has 40 clinical-stage medicines in the pipeline

The right partnerships and collaborations are leading to clinical innovation at J&J

Five Questions With Najat Khan, Ph.D., Chief Data Science Officer, Janssen R&D

Panel: Corporate Partnering to Build Valuable, Sustainable Clinical Pipelines in Gene & Cell Therapy

Janssen Pharmaceuticals - Immunology Therapeutic Area Pivots

Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue

Johnson & Johnson Innovation | Merus

Hope in the Pipeline, New Drugs: Dan Everitt

Alex introduces J&J's Strategic Framework

The Innovation and R&D Podium - Janssen Research and Development